

Insomnia

Lawrence Chan, DO

Assistant Clinical Professor
Division of Pulmonary, Critical Care and Sleep
The Ohio State University Wexner Medical Center

MedNet21

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

Learning Objectives

- · Define Insomnia Disorder
- Review Behavior Interventions
- Discuss Pharmacological Options

- Difficulty initiating sleep
- · Difficulty maintaining sleep
- Waking up earlier than desired
- Resistance to going to bed on appropriate schedule
- Difficulty sleeping without parent or caregiver intervention

Insomnia Disorder

- Fatigue/malaise
- · Attention, concentration or memory impairment
- Impaired social, family, occupational, or academic performance
- Mood disturbance/irritability
- Daytime Sleepiness

- Behavioral Problems
- Reduced motivation energy/initiative
- Proneness for error/accidents
- · Concerns about or dissatisfaction with sleep

Insomnia Disorder

Cannot be explained by inadequate opportunity or inadequate circumstances

Symptoms occur at least three times a week

Chronic - at least 3 months

Short-term - less than 3 months

Insomnia Disorder

Common

Prevalence 30-50%

Risk factors – older age, previous episodes, family history Associated – Psychiatric disorders, Medical conditions

Associated

Psychiatric disorders – Depression, Anxiety, PTSD, Substance use

Medical conditions – Pulmonary, Hypertension, Diabetes, Cancer, Chronic Pain, Heart Failure, Neurological disorders

Insomnia Disorder

Substances

Stimulants - caffeine, ADHD medications, appetite suppressants

Antidepressants - SSRI, SNRI

Beta blockers

Steroids

Alcohol, tobacco

Sleep Disorders

Sleep Apnea

Restless legs syndrome/periodic limb movements of sleep

Circadian rhythm sleep-wake disorders

Insomnia Disorder

Assessment

History

Sleep Diary/Actigraphy

Questionnaires

Sleep Studies

Treatment

Behavioral Therapies – First line Pharmacologic Treatments



Behavioral Interventions for Insomnia Case Example

Helena A. Rempala, Ph.D., ABPP, BCN

Associate Professor
Department of Psychiatry and Behavioral Health
The Ohio State University Wexner Medical Center

MedNet21
Center for Continuing Medical Education

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

Goal

Using a clinical case example to illustrate:


- Basic steps of CBT-I and BBT-I
- That One Size Does Not Fit All

No conflicts of interests to disclose.

Mrs. Luna Soleil

- 70 plus years old, petite, Caucasian, widowed, retired, cisgender female.
- Never a "great sleeper" but last 2 years she "can't sleep at all."
- No RLS, no OSA, no thyroid problems, post menopausal.
- No Hx of Bi-Polar Disorder or ADHD.

Cognitive Behavioral Model Of Insomnia



Morin et al. (1993)

Luna's Sleep Narrative: Physiological Arousal and Emotional Consequences

With the tears in her eyes she tells you a story of a life revolving around the pursuit of sleep.

She assures you with pride that despite being exhausted she "never, ever takes naps", also almost never drinks caffeine.

Her brother is very upset and her friends are upset that she is no longer participating in social gatherings.

Luna's Sleep Narrative: Habits and Maladaptive Beliefs

She stops watching TV around 9pm. In the evenings she is careful not to get too scared or agitated, she listens to music, sometimes goes for a walk, has a light supper, occasionally has a small glass of wine.

She goes to bed religiously at 10pm and "tries to fall asleep". Takes her 30 to 60 min to fall asleep. She wakes up 3-4 times a night, tosses and turns for long time, eventually falls asleep (or not). She gets out of bed for the day around 7 or 8 am.


Her room is dark and cool.

CBT-I and BBT-I One Size Does Not Fit All!

- 1. **Education:** Mechanisms of Sleep, TST, WASO, Sleep Latency, Phases of Sleep.
- 2. **Sleep Restriction**: Sleep Effciency >80%, challange to the life style.
- 3. **Stimulus Control**: Challenge to self-control.


| Best time for | for what? | | |
|---------------|-----------------------------------|--|--|
| 6:45am | Rise in blood pressure | | |
| 7:30am | Drop in Melatonin secretion | | |
| 8:30 am | Likely bowel movement | | |
| 9:00am | Rise in testosteron levels | | |
| 10:00am | Peak in alertness | | |
| 2:30pm | Peak in body coordination | | |
| 3:30pm | Fastest reaction times | | |
| 5:00pm | Best muscle and heart performance | | |
| 6:30pm | Peak in blood pressure | | |
| 7:00pm | Peak in body temperature | | |
| 9:00pm | Melatonin starts flowing | | |
| 10:30pm | Least likely bowel movement | | |
| 2:00am | Deepest Sleep | | |
| 4:30am | Nadir of body temperature | | |


Circadian Rhythm Counseling




Recommended Sleep Time by the Sleep Foundation (2014)

| Stage of Life/Age | Maximum | Optimal | Minimum |
|-----------------------|---------|---------|---------|
| Newborn 0-3 months | 18-19 | 14-17 | 11-13 |
| Infant 4-11 months | 16-18 | 12-15 | 10-11 |
| Toddler 1-2 Years | 15-16 | 11-14 | 9-10 |
| Preschooler 3-5 Years | 14 | 10-13 | 8-9 |
| School Age 6-13 Years | 12 | 9-11 | 7-8 |
| Teen 14-17 Years | 11 | 8-10 | 7 |
| Young Adult 18-25 yrs | 10-11 | 7-9 | 6 |
| Adult 26-64 Years | 10 | 7-9 | 6 |
| Older Adult 65 + | 9 | 7-8 | 5-6 |









Insomnia

Lawrence Chan, DO

Assistant Clinical Professor
Division of Pulmonary, Critical Care and Sleep
The Ohio State University Wexner Medical Center

MedNet21

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

Pharmacologic Treatments

2nd line treatment Ideally not the only treatment

Histamine

Doxepin

Tricyclic antidepressant

At low dose, selective H1 antagonist

Dosage - 3-6mg

Improved sleep by 25-38 min of total sleep time (TST)

Pro – less abuse potential

Cons – TCA (anticholinergic, QT prolongation)

Melatonin

Ramelteon

Melatonin receptor agonist, 6x more than melatonin supplements

Dosage - 8mg


Improved sleep latency 4.6min, total sleep time 7.3 min

Pro - not controlled

Con – cost, insurance coverage, small effect size

Benzodiazepine Receptor Agonists (BZRA)


Nonbenzodiazepine benzodiazepine receptor agonists Benzodiazepine



Benzodiazepine Receptor Agonists (BZRA)

Nonbenzodiazepine benzodiazepine receptor agonists

Benzodiazepine



Nonbenzodiazepine BZRA

Zolpidem

Eszopiclone

Zaleplon

Nonbenzodiazepine BZRA

Zolpidem

positive allosteric modulator intermediate half-life 1.5 to 4.5 hours
Dosage 5-10mg tablet, controlled release, sublingual, oral spray
Pro- improved TST 29 min
Con – complex sleep behaviors, high risk medication (Beers Criteria), schedule IV

Nonbenzodiazepine BZRA

Eszopiclone

longer half-life 6hrs
Dosage 1-3 mg
Pro- sleep maintenance, recent meta-analysis
Con – complex sleep behaviors, high risk medication (Beers
Criteria), schedule IV

Nonbenzodiazepine BZRA

Zaleplon

positive allosteric modulator shorter half-life 1 hr Dosage 5-20 mg Pro- reduced sleep latency 10 min, middle of the night awakenings Con – complex sleep behaviors, high risk medication (Beers Criteria), schedule IV

BZRA

Estazolam

Flurazepam

Quazepam

Temazepam


Triazolam

BZRA

Positive allosteric modulator
Tend to have longer half lives, up to 160 hours
Pro- Temazepam improved sleep latency 37min TST 99 min
Con - Risk of cumulative effects, risk with opioids, dependence, addiction, withdrawal

Dual Orexin Receptor Antagonists

Suvorexant Lemborexant Daridorexant



Dual Orexin Receptor Antagonists

Suvorexant

Antagonist at orexin receptors

Decreases wakefulness

Dosage 10-20mg

Pro – lower abuse potential, different target

Con – contraindicated in narcolepsy, schedule IV, complex sleep behaviors, cost

Dual Orexin Receptor Antagonists

Lemborexant

Dosage 5-10mg

Pro – improved sleep onset and maintenance vs zolpidem older adults (>55yo), less risk of withdrawal or rebound

Con – contraindicated in narcolepsy, schedule IV, complex sleep behaviors, cost

Dual Orexin Receptor Antagonists

Daridorexant

Dosage 25-50mg

Pro – improved sleep older adults (>65yo)

Con – contraindicated in narcolepsy, schedule IV, complex sleep behaviors, cost

Summary

Insomnia Disorder

Common with many associations

Treatment

Behavioral Therapies – First line

Pharmacologic Treatments